Skip to main content
Premium Trial:

Request an Annual Quote

Waters' Fiscal Q2 Revenue Up 17 Percent as R&D Slides and Profit Jumps 25 Percent

NEW YORK (GenomeWeb News) — Waters today said its fiscal second-quarter revenue climbed 17 percent and its net income grew by 25 percent.
 
Total revenue for the three months ended June 30 rose to $353 million from $302 million year over year.
 
Waters CEO Douglas Berthiaume said the company’s “generally broad-based” first-quarter growth sped up in the second quarter, “with continued rapid uptake of our new products and strengthening demand from life science customers, including our large pharmaceutical accounts.”
 
Berthiaume also called the first half of 2007 “very encouraging.”
 
R&D spending slid 3 percent to $19.1 million from $19.7 million in the prior-year period.
 
Net income grew to $59.9 million from $47.8 million year over year.
 
As of June 30, Waters had $544.3 million in cash and cash equivalents.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more